1. Home
  2. BEAM vs VTMX Comparison

BEAM vs VTMX Comparison

Compare BEAM & VTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$31.65

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

VTMX

Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

HOLD

Current Price

$32.01

Market Cap

2.4B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
VTMX
Founded
2017
1998
Country
United States
Mexico
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.4B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
BEAM
VTMX
Price
$31.65
$32.01
Analyst Decision
Buy
Hold
Analyst Count
14
3
Target Price
$46.00
$30.50
AVG Volume (30 Days)
2.0M
60.3K
Earning Date
02-24-2026
02-19-2026
Dividend Yield
N/A
2.17%
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
$55,701,000.00
$271,805,969.00
Revenue This Year
N/A
$13.43
Revenue Next Year
$26.52
$9.87
P/E Ratio
N/A
$45.07
Revenue Growth
N/A
11.74
52 Week Low
$13.53
$21.30
52 Week High
$36.44
$32.51

Technical Indicators

Market Signals
Indicator
BEAM
VTMX
Relative Strength Index (RSI) 56.44 57.91
Support Level $29.80 $31.70
Resistance Level $35.34 $32.45
Average True Range (ATR) 2.80 0.59
MACD 0.14 0.04
Stochastic Oscillator 55.79 78.05

Price Performance

Historical Comparison
BEAM
VTMX

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.

Share on Social Networks: